![\"Thorne](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/MXZFEDS3FVAKBIL7YSKZSNBHFI.png\")
Opens in new window<\/a><\/p>\nPrivate equity firm Yellow Wood Partners acquired Nestl\u00e9\u2019s Holistic Health portfolio for $1 billion. The sale included brands Nature\u2019s Bounty, Nuun, Osteo Bi-Flex, Gard, Puritan\u2019s Pride and Sisu, along with the associated U.S. private-label supplements business, dedicated manufacturing, packaging, warehousing and distribution operations. The transaction is subject to applicable regulatory approvals and is expected to close by the first half of 2027. It marks Yellow Wood\u2019s sixth significant carveout acquisition from five major global consumer companies, including Bayer, Reckitt, Unilever and Haleon. <\/p>\n
\u201cHolistic Health is an excellent platform of trusted brands with deep retailer relationships providing significant opportunities for continued growth,\u201d said Dana Schmaltz, partner at Yellow Wood. \u201cThe Holistic Health portfolio provides a group of specialty category leaders in various high growth sectors of the attractive VMS market, including hydration, gut health and immunity.\u201d<\/p>\n
Nestl\u00e9 will focus its resources on its premium, science-led brands Solgar and Pure Encapsulations.<\/p>\n
L Catterton and Altas Partners agreed to acquire a majority stake in Fullscript from HGGC and Snapdragon Capital. The investment will help Fullscript further expand its platform and clinical support capabilities for practitioners and extend its reach across the North American healthcare market. Financial terms of the transaction were not disclosed.<\/p>\n \u201cThe convergence of conventional and functional medicine is happening at a rapid pace. Millions of Americans are seeking trusted sources of education and treatment solutions to manage chronic conditions and prevent disease in order to live their healthiest life,\u201d said said Marc Magliacano, managing partner at L Catterton. \u201cPractitioners require a platform that can provide trusted whole-health protocols and products that is integrated into their daily practice management and assures safety and efficacy.\u201d<\/p>\n Swedish CDMO Wellma acquired Virun NutraBiosciences, strengthening its position across both the U.S. and Irish markets and expanding its international manufacturing capabilities. Founded in 2003 with operations in Los Angeles and Ireland, Virun holds over 100 patents in advanced nutrient delivery technologies including emulsion and liposomal delivery platforms for ingredients including omega-3, astaxanthin, CoQ10 and PQQ.<\/p>\n \u201cWhat attracted me to Wellma was the opportunity to continue driving Virun with the same entrepreneurial spirit that has defined us for more than two decades, while gaining access to a broader team with deep industry expertise and growth opportunities on both sides of the Atlantic,\u201d says Philip Bromley, founder and CEO of Virun. \u201cTogether with Wellma, we can better support our customers as they expand into Europe, while also helping Wellma\u2019s partners strengthen their presence in the US market.\u201d<\/p>\n Kirin Holdings Company agreed to acquire all of Canadian supplement manufacturer Jamieson Wellness Inc\u2019s issued and outstanding common shares at C$45.75 per share in cash. The transaction values Jamieson Wellness at approximately C$2.0 billion on a fully diluted equity value basis and approximately C$2.5 billion (US$1.78 billion) on an enterprise value basis.<\/p>\n \u201cToday marks an exciting new chapter for our company and for our iconic 104-year-old brand,\u201d said Mike Pilato, president and CEO of Jamieson Wellness, following the announcement. \u201cI am incredibly proud that our business will continue to flourish globally under the stewardship of a company with an even longer history and a deep commitment to health and wellness.\u201d<\/p>\n Lallemand completed its acquisition of Bio-Cat Enzymes & Microbials, combining complementary expertise in enzymes, microbial technologies, fermentation and life science innovation. The terms of the transaction were not disclosed.<\/p>\n \u201cThe acquisition will reinforce our presence in the dietary food supplement and health ingredient markets and increase our production footprint and capacity in the USA,\u201d said Antoine Chagnon, CEO of Lallemand. \u201cThis, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture and food industries.\u201d<\/p>\n Boston-based Ayana Bio and India\u2019s Zenfold Sustainable Technologies jointly acquired physical fermentation asset from the estate of defunct alt-protein firm Meati Foods for $75,000. The deal secures twelve 25,000-liter stainless steel fermentation tanks with, providing 300,000-liter capacity to scale plant cell culture technology. <\/p>\n French botanical ingredient supplier Nexira acquired Moroccan carob specialist Keragum to strengthen supply chain control and improve traceability amid increasing demand for natural, clean-label ingredients.<\/p>\n \u201cOur ambition is to invest as close as possible to production, securing high-quality raw materials while generating tangible local value,\u201d said Mathieu Dondain, VP and CEO of Nexira. \u201cTogether, Keragum and Nexira will drive the stability, sustainability and long-term growth of a market we deeply believe in.\u201d<\/p>\n European CDMO Group 1Q Health, part of Nord Holding\u2019s portfolio, acquired Swiss softgel manufacturer Gelpell AG to further strengthen the group\u2019s footprint across the DACH region. The acquisition continues Nord Holding\u2019s build-out of 1Q Health Group. The platform was formed through the purchases of ABJ alive and HKS health solutions, followed by add-on deals for VivaCell Biotechnology, Beauty Production and EHF Production. Gelpell offers services across the value chain, from product development and contract manufacturing to regulatory support and packaging.<\/p>\n Ingredient supplier SuanNutra and Carbyne Equity Partners announced plans to acquire IFF\u2019s specialty natural ingredients business, adding branded ingredients, botanical extracts, fermented vitamins and minerals, natural colors, antioxidants and flavors. The merged group of around 700 employees will operate across Spain, Slovenia and Peru and the United States. <\/p>\n Anthony Weston, group CEO of SuanNutra, said the company is focused on integrating its new operations, strengthening its commercial organization and driving growth across its six product categories, with further expansion planned in the United States and Asia while continuing to grow in Europe and Latin America. It also plans to prioritize higher-value, clinically supported branded ingredients through continued investment in clinical research and product development.<\/p>\n Private equity firm Bain Capital purchased UK-supplement brand Vitabiotics in a deal valued at approximately \u00a3900 million. Founded in 1971 by Professor Kartar Lalvani OBE, the Vitabiotics Group has built leading positions across India, China, Egypt and the wider MENA region. Its portfolio of leading brands includes Pregnacare, Perfectil, Wellman, Wellwoman, Osteocare and the Ultra range. Bain Capital will contribute local market knowledge in India, together with sector expertise, portfolio resources and global capabilities, to support Vitabiotics as it continues to scale its brands, strengthen its international platform and invest in long-term growth within key markets such as MENA and China.<\/p>\n \u201cThis direction is not about changing who we are; it is about accelerating what we can become,\u201d said Tej Lalvani, group CEO of Vitabiotics. \u201cWith Bain Capital\u2019s global expertise and investment behind us, we have a unique opportunity to expand internationally, accelerate our innovation and take our trusted brands to millions more consumers, while staying true to the science, quality and values that have defined Vitabiotics for more than 55 years.\u201d<\/p>\n cbdMD completed the acquisition of legacy supplement brand Twinlab in a deal valued at roughly $4 million, expanding into sports nutrition and longevity categories. The transaction is expected to reduce cbdMD\u2019s revenue concentration in the hemp category and mitigate risks associated with the evolving regulatory environment for hemp-derived products. The agreement follows cbdMD\u2019s earlier acquisition and integration of Bluebird Botanicals.<\/p>\n Melbourne-based Elixinol Wellness signed a binding agreement to acquire Australian personalized supplement subscription platform Vitable in an all-scrip deal worth up to $3.5 million. The structure includes $2.5 million in upfront equity, paid across five tranches in Elixinol shares, plus US$647.1K \u201cplatform kicker\u201d tied to performance milestones. <\/p>\n Vitable\u2019s service and personalized supplements are currently available across Australia, New Zealand, Singapore, the United Kingdom, Hong Kong and the Philippines, with some 7,850 active subscribers and 1.84 million customer health assessments completed through its platform. The company\u2019s international expansion was supported by A$5.5 million in funding in 2021.<\/a> Elixinol, which markets whole foods, fiber, protein and better-for-you pantry products, sold its U.S. business to Ananda Health earlier this month to focus on its core business. <\/p>\n \u201cVitable brings Elixinol an established subscription-based consumer platform, proprietary personalization capability and direct consumer relationships,\u201d said Natalie Butler, CEO and executive director at Elixinol. \u201cThese capabilities are highly complementary to our existing Australian health and wellness brands and create clear opportunities to grow customer value across the Group.\u201d<\/p>\n Solabia Group completed the acquisition of ingredient company Mibelle Biohemistry from Spanish family-owned multinational company Pers\u00e1n under terms first announced in February. Founded in Switzerland in 1991, Mibelle is known worldwide for its work in plant stem cell technology and modern biotechnology, with a portfolio covering skin beauty, healthy aging, hair care and cognitive support. Its actives are distributed in more than 50 countries.<\/p>\n Novonesis signed an agreement with the intent to acquire Australian biotechnology company MicroBioGen to strengthen its yeast capabilities for bioethanol production. The acquisition builds on Novonesis\u2019 2013 investment in MicroBioGen and its current 23% stake. The terms of the deal were not disclosed, and completion of the transaction is subject to customary regulatory approvals, including by the ACCC, Australia\u2019s national competition, consumer, fair trading and product safety regulator.<\/p>\n \u201cThis acquisition marks an additional step in our 2030 strategy,\u201d said Ester Baiget, CEO at Novonesis. \u201cIt strengthens our yeast capabilities, strengthens our R&D capabilities, and reflects our disciplined investment focus to drive growth.\u201d<\/p>\n Key takeaways<\/p>\n \u2022 Premium wellness is an attractive target: Buyers continue to prioritize scaled supplement brands with strong consumer trust, scientific positioning and established routes to market. Strategic partnerships & alliances<\/p>\n Asahi Group Foods entered into a sales agreement with Maypro Industries for the international sale of its proprietary milk peptide Lactononadecapeptide (LNDP) from July 2026 onward. Maypro, founded in 1977 by Japanese entrepreneur Steve Yamada in New York, is expected to progressively roll out the product across global markets, primarily in North America, for use in supplements and health foods. <\/p>\n This marks the Asahi Group Foods\u2019 first-time selling LNDP outside the Asahi group and to international markets. A milk peptide consisting of 19 amino acids, which was discovered in milk fermented with lactic acid bacteria, the ingredient has been reported to help maintain attention and cognitive functions that support efficiency of calculation tasks, and it is used as an ingredient in supplements and beverages sold by the Asahi Group in Japan.<\/p>\n Spanish ingredient supplier Bioiberica partnered with Ryusendo Co. to distribute its Collavant n2 native (undenatured) type II collagen joint-health ingredient to the Japanese market. The distribution partnership marks Bioiberica\u2019s first entry into the Japanese nutraceutical space and a joint-health market fueled by an aging population and a growing interest in preventative mobility support.<\/p>\n \u201cOur established reputation for circular, fully traceable production has also played an important role in bringing Collavant n2 to Japan,\u201d said Antonio Vendrell, marketing & communications director at Bioiberica. \u201cMeeting the country\u2019s stringent import and quality regulations requires complete transparency across the supply chain, an area where our processes are well-placed to deliver. Looking ahead, we see this agreement as the key that unlocks limitless opportunities in one of the world\u2019s most dynamic and innovative nutraceutical markets.\u201d<\/p>\n Norwegian marine ingredient company Calanus AS entered into an exclusive partnership with Okura Chem-Tech Corp., appointing the Osaka-based company as its exclusive importer, distributor and commercial partner for Zooca Calanus Oil in Japan.<\/p>\n \u201cJapan is at the forefront of healthy aging, product quality and nutritional innovation,\u201d said Ole Sakkestad, chief sales officer for human health & nutrition at Zooca. \u201cZooca Calanus Oil combines a distinctive marine lipid composition with strong sustainability credentials and scientific documentation. Together with Okura Chem-Tech Corp., we look forward to building a strong, long-term position in Japan.\u201d <\/p>\n The U.S.-based Organic & Natural Health Association and the Shellac & Forest Products Export Promotion Council (SHEFEXIL), an export promotion council sponsored by India\u2019s Ministry of Commerce & Industry, entered into a strategic partnership to strengthen scientific collaboration, trusted supply chains and responsible trade between the United States and India for natural health products, nutraceuticals, botanicals and functional ingredients. Planned activities include executive exchanges, regulatory roundtables, scientific forums, trade missions, buyer and seller introductions, educational programming, manufacturing and research facility visits, academic exchanges and working groups addressing emerging issues affecting the global natural health industry.<\/p>\n \u201cOur partnership with the Organic & Natural Health Association creates a stronger bridge between India and the United States for science, innovation, and responsible commerce,\u201d said Debjani Roy, Ph.D., executive director of SHEFEXIL. \u201cTogether, we are building a trusted global ecosystem through scientific collaboration, regulatory dialogue, and industry engagement that benefits both consumers and the natural health sector.\u201d<\/p>\n GNC and DFI Retail Group announced a strategic partnership to deepen access to GNC\u2019s health and wellness solutions in Singapore. This builds on a successful two-decade long collaboration between the two in Hong Kong, one of GNC\u2019s largest markets in Asia, strengthening GNC\u2019s presence in Singapore through a multi-year channel retail model. Under this expanded partnership, DFI will now also serve as GNC\u2019s exclusive wholesaler, distributor and franchisee in Hong Kong, Macau and Singapore. Products will be available in-store and online through Guardian beginning Q4 2026, as well as exclusively at GNC\u2019s standalone stores, with locations to be announced at a later stage. The partnerships comes after the May 2026 Singapore Court of Appeal decision to uphold and enforce GNC\u2019s rights to assume former GNC store leases in full.<\/p>\n \u201cFor more than three decades, Singapore consumers have placed their trust in the GNC brand,\u201d said Cheri Mullen, chief global franchise and wholesale officer at GNC. \u201cWe are proud to expand our successful partnership with DFI Retail Group beyond Hong Kong into Singapore. We look forward to reconstituting our store footprint in Singapore and remain focused on rebuilding and strengthening our presence in the market while continuing to deliver the quality, innovation and science-backed wellness solutions consumers expect from GNC.\u201d<\/p>\n Novonesis entered an agreement with precision fermentation company TurtleTree for the scaling, manufacturing and commercialization of its lactoferrin LF+ ingredient. Under the agreement, Novonesis will exclusively undertake efforts to scale, manufacture and commercialize LF+ for the early life nutrition market and will have selected commercial rights for dietary supplements. Novonesis is simultaneously making a minor investment into TurtleTree, along with 321Catalyst Ventures, the CVC-arm of Mitsui Chemicals, Inc. <\/p>\n \u201cOur aim is to make lactoferrin more accessible and cost-competitive and showcase what is achievable with precision fermentation in early life nutrition and dietary supplements,\u201d said Thomas Batchelor, senior vice president for early life and specialized nutrition at Novonesis. \u201cIf successfully scaled, this will enable customers to deliver proven health benefits to consumers more efficiently. LF+\u00aefits well in our broader portfolio of both precision fermentation projects and our specialized nutrition ingredients.\u201d<\/p>\n South Korean biohealth firm NVP Healthcare signed an exclusive supply agreement with Brazilian pharmaceutical major Marjan Farma, establishing a regional hub in Brazil to commercialize its proprietary NVP-1702 probiotic ingredient across Latin America. Under the agreement, NVP Health care will offer regulatory and technical support, while Marjan Farma will develop and commercialize finished products for the local market.<\/p>\n Wellness brand Cymbiotika partnered with personalized health and biomarker testing platform Hundred Health to offer qualifying Cymbiotika supplement subscriptions an integrated, data-driven wellness program that combines comprehensive at-home biomarker testing, medical history and wearable data to give Cymbiotika customers a personalized 100-day plan for their health.<\/p>\n \u201cFor too long, wellness has meant giving everyone the same protocol and hoping it works,\u201d said Chervin Jafarieh, co-founder and chief scientific officer of Cymbiotika. \u201cThat era is over. Cymbiotika has always believed in real intention and real science behind every formula \u2014 and this partnership is how we take that from generalized wellness to truly individualized wellness.\u201d<\/p>\n Austin-based cardiovascular health supplement company Humann established an open-ended research partnership with the UC Davis Innovation Institute for Food and Health to develop intellectual property in precision cardiovascular and metabolic health. The partnership seeks to investigate how precision nutrition approaches can improve cardiovascular health, performance and longevity to build a stronger scientific foundation for future innovation in the food and dietary supplements categories.<\/p>\n \u201cHumann started with the belief that nutrition can play a meaningful role in supporting cardiovascular health, but we\u2019ve always known there is much more to discover,\u201d said Joel Kocher, CEO and cofounder of Humann. \u201cScientific partnerships have always been central to how we build this company, and our collaboration with IIFH gives us the opportunity to deepen our understanding of how nutrition can support cardiovascular health.\u201d<\/p>\n Bevimi, a company focused on brain health and cognitive longevity, has entered an official partnership with RESOLV Proving Ground, a nonprofit dedicated to the physical and mental health of Special Operations Veterans. The partnership will combine RESOLV\u2019s physical and neuro training methods with Bevimi\u2019s targeted cognitive supplements to support mental resilience and leverage mutual insights to raise the bar for veteran care and healthspan.<\/p>\n The New York Jets and VitaCholine announced their continued collaboration to help fans understand the role of choline in supporting brain and body health, through game-day education and interactive experiences at MetLife Stadium. <\/p>\n \u201cCholine supports both brain and body health, yet many consumers still do not recognize its role,\u201d said Dr. Eric Ciappio, senior manager of nutrition science at Balchem. \u201cBy pairing the Jets\u2019 game-day reach with nutrition education, we can help fans understand why this essential nutrient matters and provide practical, science-based information they can use to make more informed nutrition choices for everyday performance and wellness.\u201d<\/p>\n USANA Health Sciences renewed its official partnership with Nordiq Canada, the national governing body for cross-country skiing in Canada. Under the renewed agreement, USANA will continue supplying Nordiq Canada\u2019s elite athletes with premium, NSF Certified for Sport nutritional products designed to support performance, normal muscle recovery after exercise and long-term health through the 2030 Olympic Winter Games and beyond.<\/p>\n \u201cCanada has a passionate and knowledgeable fan base for cross-country skiing, and Nordiq Canada\u2019s athletes inspire millions of Canadians every time they compete,\u201d said Tracie Kenzora, general manager of Canada at USANA. \u201cThis renewal is a reflection of USANA\u2019s deep commitment to the Canadian market and to the athletes and communities we serve here. We\u2019re thrilled to continue standing behind some of the country\u2019s finest athletes as they chase their dreams on the world stage.\u201d<\/p>\n Wellness platform and community TRU47 announced a strategic partnership with USA Pickleball. The partnership will introduce TRU47\u2014which initially focused on medicinal silver and grounding products but has since expanded to offer supplements\u2014to USA Pickleball\u2019s nationwide community through digital marketing, player education, product sampling, ambassador and influencer campaigns, live-event activations, original content and e-commerce initiatives. USA Pickleball surpassed 130,000 members in 2025 and is supported by more than 1,800 ambassadors nationwide. <\/p>\n \u201cOur partnership with USA Pickleball is about much more than sponsorship,\u201d said Edward Bugniazet, CEO of Rye Strategic Partners and Chairman of TRU47. \u201cPickleball is a demanding, fast-growing sport, and its players represent the exact active, health-conscious community our products are designed for. We\u2019re building a curated wellness platform and community that directly supports these everyday athletes\u2019 performance and recovery needs through education, authentic content and trusted, innovative tools.\u201d <\/p>\n Key takeaways<\/p>\n \u2022 International market access is a central partnership objective: Suppliers and brands are working with local distributors, importers and retailers to navigate new markets and accelerate commercialization. Investments & stakes<\/p>\n Tiny Health closed $33 million in Series B funding, led by B Capital, bringing the gut and vaginal microbiome intelligence platform\u2019s total funding to $46 million. New investors include Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures, alongside continued support from Spero Ventures, TheVentureCity, Overwater Ventures and others. The gut and vaginal microbiome intelligence platform will use the capital to advance clinical research and interventional studies, expand its healthcare practitioner education, scale its Powered by Tiny platform and accelerate TinyAI, an AI trained on Tiny Health\u2019s proprietary dataset of nearly 200,000 microbiome profiles to deliver personalized, science-backed guidance tied directly to a user\u2019s results. In tandem with the raise, Tiny Health announced the launch of a $5 million Microbiome Research Program to accelerate microbiome research. <\/p>\n India-based ingredient supplier Nutriventia announced that it had closed a strategic growth investment from NDude Labs, a healthcare\/wellness investment holding company with operations in India and the United States. The capital is earmarked for clinical R&D, expansion of proprietary branded ingredients, scaling its delivery platform, establishing dedicated U.S. commercial operations and subsequent expansion into Europe and APAC. <\/p>\n \u201cWe built our proprietary delivery platforms to solve genuine pharmaceutical-grade challenges around bioavailability, stability and efficacy,\u201d said Vishal Shah, co-founder and managing director at Nutriventia. \u201cThis partnership ensures that we can deepen our clinical pipeline and advance our delivery platforms without compromising scientific rigor.\u201d<\/p>\n Utah-based CDMO WB Blends, backed by private equity firm The Riverside Company, acquired a majority stake Oregon-based consumer products company Yellow Emperor, expanding its capabilities beyond capsules and powders into tinctures, extracts and liquid herbal supplements. Yellow Emperor, founded in 1981, will continue to operate under its current name, day-to-day operations will remain unchanged, and products will continue to be manufactured in the same facilities.<\/p>\n \u201cConsumers keep gravitating toward vitamin, mineral and supplement (VMS) products and natural wellness solutions, creating attractive long-term growth for CDMOs with specialized capabilities,\u201d said Brad Roberts, co-chief investment officer of Riverside\u2019s Capital Appreciation strategy. \u201cYellow Emperor is a natural complement to Western Botanicals, deepening its liquid platform, strengthening R&D, and opening new ways to serve customers.\u201d<\/p>\n David Beckham-backed wellness brand IM8 secured a novel $1 billion growth-financing structure from General Catalyst. Under the arrangement, General Catalyst\u2019s Customer Value Fund finances up to 70% of IM8\u2019s marketing spend, with IM8 retaining full discretion over facility utilization. In return, General Catalyst receives capped share of income that is tied to the performance of customer cohorts financed through the program, capped at predetermined levels. Once General Catalyst has recovered its investment and capped return on any given monthly cohort, all subsequent value from those customers accrues entirely and permanently to IM8. The arrangement does not involve the issuance of any equity, warrants or convertible instruments to General Catalyst, and is tracked separately for each monthly cohort of customers.<\/p>\n \u201cNineteen months ago, IM8 was an idea David Beckham and I were building around one belief: that people deserve premium science-backed products they can trust every day,\u201d Danny Yeung, CEO and co-founder of parent company Prenetics, shared in a press July 14 press release. \u201cToday it\u2019s the fastest-growing premium supplement brand ever recorded, and General Catalyst\u2019s $1 billion commitment validates the strength of the cohort economics we\u2019ve built. Every mature customer cohort since launch has exceeded the performance thresholds General Catalyst diligenced against, cohort after cohort, in the deepest diligence process I\u2019ve been through as a founder.\u201d<\/p>\n With the financing, IM8 plans to accelerate brand and marketing across its 43 countries without issuing a single share to fund it as it continues to build a multi-billion-dollar global consumer health brand. <\/p>\n Novonesis announced plans to invest \u20b96,660 crore (over $694 million) in Maharashtra over the next 24 to 36 months, with a significant portion expected to go towards developing unused land to expand its manufacturing facility in the industrial district of Patalganga to meet the growing domestic demand for biofuels, agricultural biologicals and health solutions. The expanded facility is scheduled to be fully operational by 2030. In addition to Patalganga, Novonesis operates a facility in Wada, Maharashtra, producing enzymes, health ingredients, and nutrition products for both domestic and export markets. The investment aligns with the company\u2019s broader strategy focusing on customers in emerging markets across the Middle East, India and Africa.<\/p>\n Unilever announced plans to develop a new global innovation center in New Haven, Conn., opening by spring 2029. The multinational consumer goods company says that the $270-million investment reflects its belief in science-led growth and the increasingly central role of the United States in driving innovation across its business. The long-term investment includes $50 million in capital expenditure\u2014the company\u2019s largest in the United States in 40 years\u2014and builds on $15 billion invested in its U.S. business over the past decade, across both acquisitions and capital projects.<\/p>\n \u201cThis new center is where we\u2019ll innovate at the intersection of science, technology and culture,\u201d Herrish Patel, president of Unilever USA and CEO of Personal Care North America, shared in a release. \u201cAs the US becomes a center of gravity for Unilever, we\u2019re harnessing the best of American innovation to match our growth ambition here in the US and around the world.\u201d<\/p>\n![\"Nestle](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/2B4DT46ZGNFVVNJUWAKLF6DXYI.png\")
Opens in new window<\/a><\/p>\n![\"Virun](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/5FXV2UZGR5FNXNXCYKA2XSQH5I.png\")
https:\/\/www.nutraingredients.com\/Article\/2026\/07\/27\/fast-growing-cdmo-wellma-acquires-virun-nutrabiosciences\/ (NutraIngredients)<\/p>\n![\"Jamieson](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/M4VGHLVIXVGRZENZQRNXQKPLUM.png\")
Opens in new window<\/a><\/p>\n![\"Bio-Cat](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/VNBLS5K76FAXDJTZRZE7W4KQIQ.png\")
Opens in new window<\/a><\/p>\n![\"Keragum](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/CA2RYUX6CFDIPA3PF3AXIY5ELA.png\")
Opens in new window<\/a><\/p>\n![\"IFF](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/6MGFFL4B7NAHXMF5LIIGA4PGBY.png\")
Opens in new window<\/a><\/p>\n![\"Twinlab](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/FYJYEMIOUFFRHK7PMOPGAIAZQI.png\")
Opens in new window<\/a><\/p>\n![\"Vitable](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/LEJU4N35DZBODIUOPFKRUZASL4.png\")
Opens in new window<\/a><\/p>\n![\"Mibelle](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/PQ3PV4KTSRELRHHAK7U426X3OI.png\")
Mibelle Biochemistry acquisition NI coverage (NutraIngredients)<\/p>\n
\u2022 Portfolio reshaping is accelerating: Large companies are divesting noncore assets and concentrating resources on premium, differentiated and science-led businesses.
\u2022 Private equity remains a major force in consolidation: Private equity firms are using carveouts, platform investments and add-on acquisitions to build broader health, wellness and manufacturing portfolios.
\u2022 Manufacturing scale and technical specialization are in demand: Acquirers are seeking expanded capacity and expertise in delivery technologies, fermentation, enzymes, microbials, softgels and other specialized formats.
\u2022 Vertical integration is strengthening supply resilience: Ingredient-focused transactions reflect growing interest in traceability, raw-material access, quality control and greater oversight of production.
\u2022 Digital and personalized health are moving into the mainstream: Practitioner integration, subscription models, proprietary data and direct consumer relationships are becoming increasingly valuable deal assets.
\u2022 Cross-border expansion remains a recurring objective: Acquisitions are being used to enter new markets, broaden distribution and combine global reach with local manufacturing and regulatory expertise.<\/p>\n![\"GNC](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/DHW7C7SWDFGQ3PONQRCTK4OY7A.png\")
Opens in new window<\/a><\/p>\n![\"NVP](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/QPZ6FVGF45F4JOV4SNT5LN2WZU.png\")
Opens in new window<\/a><\/p>\n![\"Humann](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/JT5RBH4HINAGJC7Z4LOL7CYVIA.png\")
Opens in new window<\/a><\/p>\n
\u2022 Local expertise is becoming critical to expansion: Regional partners provide regulatory knowledge, established channels and market-specific capabilities that can reduce barriers to entry.
\u2022 Science and commercialization are increasingly intertwined: Alliances are pairing research, technical validation and intellectual-property development with manufacturing scale and market execution.
\u2022 Personalization is driving new ecosystem partnerships: Biomarker testing, wearable data and tailored protocols are being integrated with supplement offerings to create more individualized wellness programs.
\u2022 Sports and community platforms as education channels: Brands continue to use athlete, fan and active-lifestyle partnerships to build awareness through education, events and digital engagement.
\u2022 Partnerships are broadening beyond conventional distribution: Agreements increasingly combine research, manufacturing, education, marketing, product development and long-term commercial rights.<\/p>\n![\"Tiny](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/DQCWZN35OJFZ7ARSJKJDH56WUQ.png\")
Opens in new window<\/a><\/p>\n![\"IM8](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/ZIK3VVQD7NH5XLID33VNROYWGM.png\")
Opens in new window<\/a><\/p>\n
![\"Unilever](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/7L2TCFTZ3JCCVNSWQJO7MLBELA.png\")
Opens in new window<\/a><\/p>\n![\"Function](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/WYE7I66CRVB3VELCJLXXROCM5I.png\")
Opens in new window<\/a><\/p>\n